Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
暂无分享,去创建一个
R. Beroukhim | K. Ligon | S. Mueller | S. Ramkissoon | S. Leary | P. Bandopadhayay | M. Fouladi | D. Parsons | B. Marini | Amy L. Pasternak | S. Chi | Zachary Miklja | Stefanie Stallard | T. Nicolaides | Cassie Kline-Nunnally | B. Cole | Brendan Mullan | Amy K. Bruzek | Angela C Gauthier | Taylor Garcia | C. Atchison | C. Koschmann | B. Mullan | T. Garcia | Angela C. Gauthier | Z. Miklja
[1] David T. W. Jones,et al. EWSR1‐PATZ1 gene fusion may define a new glioneuronal tumor entity , 2018, Brain pathology.
[2] P. Robertson,et al. CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response , 2018, Acta Neuropathologica Communications.
[3] David T. W. Jones,et al. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial , 2018, Cancer cell.
[4] A. Chinnaiyan,et al. Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. , 2018, JCO precision oncology.
[5] J. Ojemann,et al. Year 1 in the Molecular Era of Pediatric Brain Tumor Diagnosis: Application of Universal Clinical Targeted Sequencing in an Unselected Cohort of Children. , 2018, JCO precision oncology.
[6] M. Chintagumpala,et al. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas , 2018, Pediatric blood & cancer.
[7] Rachel A. Kudgus,et al. A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111) , 2017, Pediatric blood & cancer.
[8] Kun Mu,et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.
[9] A. Chinnaiyan,et al. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. , 2017, Translational research : the journal of laboratory and clinical medicine.
[10] James Suh,et al. Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures , 2017, The oncologist.
[11] A. Chinnaiyan,et al. Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event , 2017, npj Precision Oncology.
[12] P. Robertson,et al. Identification and targeting of an FGFR fusion in a pediatric thalamic “central oligodendroglioma― , 2018 .
[13] W. Vandertop,et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma , 2017, Journal of Neuro-Oncology.
[14] K. Ligon,et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Mariella G. Filbin,et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors , 2017, Neuro-oncology.
[16] Robert J. Lonigro,et al. Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.
[17] P. Northcott,et al. Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Ferrari,et al. Front‐line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group , 2017, Pediatric blood & cancer.
[19] I. Pollack,et al. A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study. , 2017 .
[20] T. MacDonald,et al. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high‐grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study , 2017, Pediatric blood & cancer.
[21] P. Wen,et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma , 2017, Oncotarget.
[22] Jindong Chen,et al. Immune Checkpoint in Glioblastoma: Promising and Challenging , 2017, Front. Pharmacol..
[23] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[24] G. Mason,et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. , 2017, Journal of neurosurgery. Pediatrics.
[25] D. Ziegler,et al. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models , 2017, PloS one.
[26] Arie Perry,et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy , 2016, Neuro-oncology.
[27] David T. W. Jones,et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.
[28] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[29] M. Prados,et al. Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas , 2017, Journal of Neuro-Oncology.
[30] Roland Eils,et al. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma , 2016, Nature Medicine.
[31] B. Geoerger,et al. CNS tumoursThe first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas , 2016 .
[32] D. Merico,et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Chris Jones,et al. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma , 2016, Oncotarget.
[34] I. Pollack,et al. Nonrandomized comparison of neurofibromatosis type 1 and non–neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low‐grade glioma: A report from the Children's Oncology Group , 2016, Cancer.
[35] J. McPherson,et al. Coming of age: ten years of next-generation sequencing technologies , 2016, Nature Reviews Genetics.
[36] P. Burger,et al. Management of pediatric intracranial low-grade gliomas: long-term follow-up after radiation therapy , 2016, Child's Nervous System.
[37] D. Ferguson,et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma , 2016, Science Translational Medicine.
[38] H. Gan,et al. Prolonged disease control with MEK inhibitor in neurofibromatosis type I‐associated glioblastoma , 2016, Journal of clinical pharmacy and therapeutics.
[39] Somak Roy,et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. , 2016, Neuro-oncology.
[40] Roland Eils,et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.
[41] J. MacKeigan,et al. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. , 2015, Neuro-oncology.
[42] J. Ptak,et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord , 2015, Proceedings of the National Academy of Sciences.
[43] M. Sahin,et al. Tuberous sclerosis complex. , 2015, Pediatric clinics of North America.
[44] Nicholas J. Wang,et al. Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.
[45] D. Merico,et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] K. Kurian,et al. Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas , 2015, Front. Oncol..
[47] R. Riccardi,et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? , 2015, Journal of chemotherapy.
[48] P. Anderson. Futility versus utility of marrow assessment in initial Ewing sarcoma staging workup , 2014, Pediatric blood & cancer.
[49] E. Roach,et al. Tuberous sclerosis complex. , 2015, Handbook of clinical neurology.
[50] A. Gajjar,et al. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy , 2014, BMC Cancer.
[51] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[52] David T. W. Jones,et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.
[53] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[54] D. Kirsch,et al. PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma , 2013, PloS one.
[55] Y. Miyakita,et al. Secondary hematological malignancies associated with temozolomide in patients with glioma. , 2013, Neuro-oncology.
[56] D. Brat,et al. PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.
[57] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[58] B. Garcia,et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.
[59] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[60] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[61] K. Ligon,et al. BRAF Duplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper , 2012, Journal of neuropathology and experimental neurology.
[62] I. Pollack,et al. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. , 2012, Neuro-oncology.
[63] Rebecca A. Ihrie,et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy , 2012, Proceedings of the National Academy of Sciences.
[64] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[65] T. Tihan,et al. Pathologic Characteristics of Pediatric Intracranial Pilocytic Astrocytomas and Their Impact on Outcome in 3 Countries: A Multi-institutional Study , 2012, The American journal of surgical pathology.
[66] L. Garraway,et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. , 2011, The Journal of molecular diagnostics : JMD.
[67] R. McLendon,et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.
[68] H. Zentgraf,et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.
[69] J. Wisoff,et al. Primary Neurosurgery for Pediatric Low-Grade Gliomas: A Prospective Multi-Institutional Study From the Children's Oncology Group , 2011, Neurosurgery.
[70] Daniel J Brat,et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. , 2011, Neuro-oncology.
[71] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[72] A. Byars,et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.
[73] G. Armstrong. Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[74] M. Prados,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.
[75] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[76] C. Kramm,et al. Intensive chemotherapy improves survival in pediatric high‐grade glioma after gross total resection: results of the HIT‐GBM‐C protocol , 2010, Cancer.
[77] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[78] Thomas E Merchant,et al. Brain tumors across the age spectrum: biology, therapy, and late effects. , 2010, Seminars in radiation oncology.
[79] T. Merchant,et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[81] S. Jóźwiak,et al. Tuberous sclerosis , 2008, The Lancet.
[82] P. Houghton,et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[84] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[85] D. Hargrave,et al. Diffuse brainstem glioma in children: critical review of clinical trials. , 2006, The Lancet. Oncology.
[86] E. Thiele,et al. Subependymal giant cell tumors in tuberous sclerosis complex , 2004, Neurology.
[87] G. Almouzni,et al. Histone H3.1 and H3.3 Complexes Mediate Nucleosome Assembly Pathways Dependent or Independent of DNA Synthesis , 2004, Cell.
[88] M. Prados,et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen , 1997, Journal of Neuro-Oncology.
[89] Audrey E. Evans,et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial , 1989, Journal of Neuro-Oncology.
[90] H. Winn. Youmans Neurological Surgery , 2003 .
[91] Hitoshi Takahashi,et al. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. , 2002, Neurologia medico-chirurgica.
[92] David J. Kwiatkowski,et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[93] M. Cartmill,et al. Diffuse brain stem glioma A review of stereotactic biopsies , 1999, Child's Nervous System.
[94] M. Berger,et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. , 1998, Journal of neurosurgery.
[95] M. Ewen,et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. , 1993, Genes & development.
[96] W. Whisler,et al. Youmans' Neurological Surgery: , 1990 .
[97] J. Higginson,et al. International Agency for Research on Cancer. , 1968, WHO chronicle.